Free Trial

Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis

Iovance Biotherapeutics logo
$1.78 +0.03 (+1.71%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$1.78 0.00 (0.00%)
As of 05/23/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Iovance Biotherapeutics Stock (NASDAQ:IOVA)

Key Stats

Today's Range
$1.67
$1.79
50-Day Range
$1.66
$3.63
52-Week Range
$1.64
$12.51
Volume
7.85 million shs
Average Volume
8.64 million shs
Market Capitalization
$594.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.30
Consensus Rating
Moderate Buy

Company Overview

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Iovance Biotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
89th Percentile Overall Score

IOVA MarketRank™: 

Iovance Biotherapeutics scored higher than 89% of companies evaluated by MarketBeat, and ranked 114th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Iovance Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 6 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Iovance Biotherapeutics has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Iovance Biotherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($1.24) to ($0.88) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Iovance Biotherapeutics is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Iovance Biotherapeutics is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Iovance Biotherapeutics has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    27.57% of the float of Iovance Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Iovance Biotherapeutics has a short interest ratio ("days to cover") of 6.3.
  • Change versus previous month

    Short interest in Iovance Biotherapeutics has recently increased by 4.48%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Iovance Biotherapeutics does not currently pay a dividend.

  • Dividend Growth

    Iovance Biotherapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    27.57% of the float of Iovance Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Iovance Biotherapeutics has a short interest ratio ("days to cover") of 6.3.
  • Change versus previous month

    Short interest in Iovance Biotherapeutics has recently increased by 4.48%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Iovance Biotherapeutics has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 45 news articles for Iovance Biotherapeutics this week, compared to 8 articles on an average week.
  • Search Interest

    61 people have searched for IOVA on MarketBeat in the last 30 days. This is an increase of 74% compared to the previous 30 days.
  • MarketBeat Follows

    17 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 70% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Iovance Biotherapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.10% of the stock of Iovance Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    77.03% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Iovance Biotherapeutics' insider trading history.
Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

IOVA Stock News Headlines

Watch This Robotics Demo Before July 23rd
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
See More Headlines

IOVA Stock Analysis - Frequently Asked Questions

Iovance Biotherapeutics' stock was trading at $7.40 on January 1st, 2025. Since then, IOVA shares have decreased by 75.9% and is now trading at $1.78.
View the best growth stocks for 2025 here
.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) released its earnings results on Thursday, May, 8th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by $0.11. The company's revenue for the quarter was up 6795.1% on a year-over-year basis.
Read the conference call transcript
.

Top institutional shareholders of Iovance Biotherapeutics include Vanguard Group Inc. (8.32%), Long Focus Capital Management LLC (2.77%), UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC (1.73%) and Goldman Sachs Group Inc. (1.67%). Insiders that own company stock include Wayne P Rothbaum, Merrill A Mcpeak, Iain D Dukes, Ryan D Maynard and Frederick G Vogt.
View institutional ownership trends
.

Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Iovance Biotherapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), CrowdStrike (CRWD) and ServiceNow (NOW).

Company Calendar

Last Earnings
5/08/2025
Today
5/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IOVA
Fax
N/A
Employees
500
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$13.30
High Stock Price Target
$25.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+647.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
12 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-444,040,000.00
Net Margins
-451.25%
Pretax Margin
-458.01%

Debt

Sales & Book Value

Annual Sales
$212.68 million
Price / Cash Flow
N/A
Book Value
$2.28 per share
Price / Book
0.78

Miscellaneous

Free Float
267,902,000
Market Cap
$594.40 million
Optionable
Optionable
Beta
1.06

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:IOVA) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners